10x Genomics (TXG) Stock Forecast & Price Target

Compare

1,082 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TXG Analyst Ratings

Moderate Buy

4 Buy

7 Hold

0 Sell

Based on 11 analysts giving stock ratings to

10x

Genomics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TXG Stock 12 Month Forecast

Average Price Target

$13.00

▲(6.12%Upside)

Based on 11 Wall Street analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is $13.00 with a high forecast of $18.00 and a low forecast of $9.00. The average price target represents a 6.12% change from the last price of $12.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","12":"$12","17":"$17","22":"$22","27":"$27"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,12,17,22,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.45,10.107692307692307,10.765384615384615,11.423076923076923,12.080769230769231,12.73846153846154,13.396153846153846,14.053846153846154,14.711538461538462,15.36923076923077,16.026923076923076,16.684615384615384,17.342307692307692,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.45,9.723076923076922,9.996153846153845,10.269230769230768,10.542307692307691,10.815384615384614,11.088461538461537,11.361538461538462,11.634615384615383,11.907692307692308,12.18076923076923,12.453846153846154,12.726923076923077,{"y":13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.45,9.415384615384614,9.38076923076923,9.346153846153845,9.311538461538461,9.276923076923076,9.242307692307692,9.207692307692307,9.173076923076923,9.138461538461538,9.103846153846154,9.069230769230769,9.034615384615385,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.92,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.42,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.59,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$18.00

Average Price Target$13.00

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$13

Hold

6.12%

Upside

Reiterated

07/02/25

10x Genomics' overall stock score is driven by its strong technical momentum and operational efficiencies. However, significant challenges in profitability and valuation, coupled with uncertainties in funding and declining instrument revenue, weigh down the score.

Kyle Mikson CFACanaccord Genuity

Canaccord Genuity

$15

Buy

22.45%

Upside

Reiterated

06/30/25

10x Genomics: Strategic Positioning and Growth Potential Justify Buy Rating

Michael RyskinBank of America Securities

Bank of America Securities

$12→$13

Hold

6.12%

Upside

Reiterated

06/26/25

10x Genomics (TXG) Receives a Hold from Bank of America Securities

Luke SergottBarclays

Barclays

$12→$13

Buy

6.12%

Upside

Reiterated

06/24/25

10x Genomics price target raised to $13 from $12 at Barclays10x Genomics price target raised to $13 from $12 at Barclays

Isla CarelynxAI Firm

AI Firm

$9→$11

Hold

-10.20%

Downside

Reiterated

06/11/25

Daniel BrennanTD Cowen

TD Cowen

$11

Hold

-10.20%

Downside

Reiterated

06/06/25

Tejas SavantMorgan Stanley

Morgan Stanley

$18

Buy

46.94%

Upside

Reiterated

05/19/25

10x Genomics: Buy Rating Affirmed Amid Consumable Growth and Legal Resolutions

Matt LarewWilliam Blair

William Blair

―

Hold

―

Reiterated

05/14/25

Hold Rating Maintained for 10x Genomics Amid Settlement Gains and Macroeconomic Challenges

Puneet SoudaLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (NASDAQ: SCPH), 10x Genomics (NASDAQ: TXG) and Kura Oncology (NASDAQ: KURA)

John SourbeerUBS

UBS

$14→$12

Hold

-2.04%

Downside

Reiterated

05/13/25

10X Genomics (TXG) PT Lowered to $12 at UBSUBS analyst John Sourbeer lowered the price target on 10X Genomics (NASDAQ: TXG) to $12.00 (from $14.00) while maintaining a Neutral rating.

Rachel VatnsdalJ.P. Morgan

J.P. Morgan

$12→$9

Hold

-26.53%

Downside

Reiterated

05/09/25

10x Genomics price target lowered to $9 from $12 at JPMorgan10x Genomics price target lowered to $9 from $12 at JPMorgan

Daniel AriasStifel Nicolaus

Stifel Nicolaus

$18→$15

Buy

22.45%

Upside

Reiterated

05/09/25

Stifel Nicolaus Reaffirms Their Buy Rating on 10x Genomics (TXG)

Patrick B DonnellyCiti

Citi

$20→$15

Buy

22.45%

Upside

Reiterated

03/04/25

10x Genomics price target lowered to $15 from $20 at Citi10x Genomics price target lowered to $15 from $20 at Citi

Subbu NambiGuggenheim

Guggenheim

―

Hold

―

Reiterated

02/23/25

We expect TXG to share more on what these new products will mean for the research community and their competitive positioning at AGBT, especially given other updates from the likes of BRKR and ILMN heading into the conference. *** We will be attending AGBT in person. If you are there and want to meet, let us know. Also, please email us if you want to schedule a time to chat after.

Tycho PetersonJefferies

Jefferies

$19

Buy

55.10%

Upside

Reiterated

02/12/25

Positive Outlook for 10x Genomics Amid Strong Financials and Growth ProspectsWe see little middle ground, as bulls argue conservatism after tough few years and newer CFO set up for beats, while bears see NIH downside, competitive dynamics and little valuation support.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$13

Hold

6.12%

Upside

Reiterated

07/02/25

Kyle Mikson CFACanaccord Genuity

Canaccord Genuity

$15

Buy

22.45%

Upside

Reiterated

06/30/25

10x Genomics: Strategic Positioning and Growth Potential Justify Buy Rating

Michael RyskinBank of America Securities

Bank of America Securities

$12→$13

Hold

6.12%

Upside

Reiterated

06/26/25

10x Genomics (TXG) Receives a Hold from Bank of America Securities

Luke SergottBarclays

Barclays

$12→$13

Buy

6.12%

Upside

Reiterated

06/24/25

10x Genomics price target raised to $13 from $12 at Barclays10x Genomics price target raised to $13 from $12 at Barclays

Isla CarelynxAI Firm

AI Firm

$9→$11

Hold

-10.20%

Downside

Reiterated

06/11/25

Daniel BrennanTD Cowen

TD Cowen

$11

Hold

-10.20%

Downside

Reiterated

06/06/25

Tejas SavantMorgan Stanley

Morgan Stanley

$18

Buy

46.94%

Upside

Reiterated

05/19/25

10x Genomics: Buy Rating Affirmed Amid Consumable Growth and Legal Resolutions

Matt LarewWilliam Blair

William Blair

―

Hold

―

Reiterated

05/14/25

Hold Rating Maintained for 10x Genomics Amid Settlement Gains and Macroeconomic Challenges

Puneet SoudaLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (NASDAQ: SCPH), 10x Genomics (NASDAQ: TXG) and Kura Oncology (NASDAQ: KURA)

John SourbeerUBS

UBS

$14→$12

Hold

-2.04%

Downside

Reiterated

05/13/25

10X Genomics (TXG) PT Lowered to $12 at UBSUBS analyst John Sourbeer lowered the price target on 10X Genomics (NASDAQ: TXG) to $12.00 (from $14.00) while maintaining a Neutral rating.

Rachel VatnsdalJ.P. Morgan

J.P. Morgan

$12→$9

Hold

-26.53%

Downside

Reiterated

05/09/25

10x Genomics price target lowered to $9 from $12 at JPMorgan10x Genomics price target lowered to $9 from $12 at JPMorgan

Daniel AriasStifel Nicolaus

Stifel Nicolaus

$18→$15

Buy

22.45%

Upside

Reiterated

05/09/25

Stifel Nicolaus Reaffirms Their Buy Rating on 10x Genomics (TXG)

Patrick B DonnellyCiti

Citi

$20→$15

Buy

22.45%

Upside

Reiterated

03/04/25

10x Genomics price target lowered to $15 from $20 at Citi10x Genomics price target lowered to $15 from $20 at Citi

Subbu NambiGuggenheim

Guggenheim

―

Hold

―

Reiterated

02/23/25

Tycho PetersonJefferies

Jefferies

$19

Buy

55.10%

Upside

Reiterated

02/12/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 10x Genomics

1 Month

xxx

Success Rate

9/19 ratings generated profit

Average Return

-2.76%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.37% of your transactions generating a profit, with an average return of -2.76% per trade.

3 Months

xxx

Success Rate

8/19 ratings generated profit

Average Return

-4.59%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of -4.59% per trade.

1 Year

Patrick B DonnellyCiti

Success Rate

9/19 ratings generated profit

Average Return

+4.25%

reiterated a buy rating 4 months ago

Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +4.25% per trade.

2 Years

xxx

Success Rate

6/22 ratings generated profit

Average Return

-21.21%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 27.27% of your transactions generating a profit, with an average return of -21.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TXG Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TXG has received 7 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. TXG average Analyst price target in the past 3 months is 13.00.

Each month's total comprises the sum of three months' worth of ratings.

TXG Financial Forecast

TXG Earnings Forecast

Next quarter’s earnings estimate for TXG is -$0.37 with a range of -$0.45 to -$0.30. The previous quarter’s EPS was -$0.28. TXG beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year TXG has Preformed in-line its overall industry.

TXG Sales Forecast

Next quarter’s sales forecast for TXG is $139.32M with a range of $137.79M to $140.62M. The previous quarter’s sales results were $154.88M. TXG beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TXG has Preformed in-line its overall industry.

TXG Stock Forecast FAQ

What is TXG’s average 12-month price target, according to analysts?

Based on analyst ratings, 10x Genomics Inc’s 12-month average price target is 13.00.

What is TXG’s upside potential, based on the analysts’ average price target?

10x Genomics Inc has 6.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TXG a Buy, Sell or Hold?

10x Genomics Inc has a consensus rating of Moderate Buy which is based on 4 buy ratings, 7 hold ratings and 0 sell ratings.

What is 10x Genomics Inc’s price target?

The average price target for 10x Genomics Inc is 13.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $9.00. The average price target represents 6.12% Increase from the current price of $12.25.

What do analysts say about 10x Genomics Inc?

10x Genomics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of TXG?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

10x Genomics (TXG) Stock Forecast & Price Target

TXG Analyst Ratings

TXG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering 10x Genomics

TXG Analyst Recommendation Trends

TXG Financial Forecast

TXG Earnings Forecast

TXG Sales Forecast

TXG Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts